Patents Issued in February 15, 2024
-
Publication number: 20240050464Abstract: In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example pruritus, a disorder related to elevated serum cholesterol concentration, or reducing elevated low-density lipoprotein cholesterol (LDL) concentration in a patient.Type: ApplicationFiled: September 25, 2023Publication date: February 15, 2024Applicant: Viscera Labs, Inc.Inventors: Stephen TAGLIENTI, Steven L. PETRUCCELLI
-
Publication number: 20240050465Abstract: Hydrogen water for inhibition of alcoholic hepatopathy, to be mixed with ethanol, has a dissolved hydrogen concentration of 550 ppb to 5600 ppb. The concentration of the ethanol in the hydrogen water when mixed with the ethanol is 1% to 4%.Type: ApplicationFiled: January 11, 2022Publication date: February 15, 2024Inventor: Taichi HARA
-
Publication number: 20240050466Abstract: A nutritional supplement composition formulated having antioxidant and anti-inflammatory nutrients reduces cellular biomarkers of DNA damage and improves cellular regenerative capacity.Type: ApplicationFiled: December 20, 2021Publication date: February 15, 2024Inventors: Caroline Felicity BULL, Michael FENECH, Scott William POXON, Bernardus Jan-Willem VAN KLINKEN
-
Publication number: 20240050467Abstract: A system and method of use for an operational halotherapy device and red light device in an enclosed space. The halotherapy and red light system generally comprise a machine disposed in the enclosed space that disperses salt particles into the air, and includes a red light device that emits red light waves. The combination of both devices produces a refractory phenomenon when the red light waves make contact with the salt particles dispersed in the air to cause a plethora of multi-dimensional dispersions of light waves. Moreover, every time a salt particle makes contact with a red light wave, a portion of the wave light is absorbed by the particle and its temperature increases, lessening the moisture in the particle. The lessening of moisture in the particle dries the particle further, which enhances the therapeutic properties of the inhalable salt particle.Type: ApplicationFiled: October 17, 2023Publication date: February 15, 2024Inventors: John J. Brier, JR., Edwin A. Weihenmayer, IV
-
Publication number: 20240050468Abstract: A formulation in gel form comprising erbium borate nanoparticles, at least one surfactant and at least one gelling agent with carrier gel properties for use in prevention and treatment of wound scars is provided.Type: ApplicationFiled: November 9, 2021Publication date: February 15, 2024Applicant: YEDITEPE UNIVERSITESIInventors: Fikrettin SAHIN, Erhan AYSAN, Pakize Neslihan TASLI, Oguz Kaan KIRBAS, Batuhan Turhan BOZKURT, Berna BULBUL
-
Publication number: 20240050469Abstract: Novel dinuclear silver(I) pyrazolido complexes and methods of synthesizing them are provided. Advantageously, the novel silver(I) pyrazolido complexes have excellent antimicrobial activity and methods of using said complexes to treat bacterial, fungal, and viral infections are also provided.Type: ApplicationFiled: October 9, 2023Publication date: February 15, 2024Applicant: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: RAPHAEL G. RAPTIS, INDRANIL CHAKRABORTY, SHAMBHU KANDEL
-
Publication number: 20240050470Abstract: A method to inhibit reperfusion injury to a tissue that has experienced ischemia comprising treating the ischemic tissue with an antioxidant solution prior to or in conjunction with reperfusion of blood into the ischemic tissue pursuant to artery bypass surgery, angioplasty or in conjunction with an angiogram. The antioxidant solution is comprised of water, dissolved salts of calcium, potassium, magnesium, sodium, one or more buffers, L-Arginine, glucose, glutathione, and ascorbic acid and wherein the solution is ionically and pH balanced to a physiologic pH, preferably 7.2-7.4.Type: ApplicationFiled: October 18, 2023Publication date: February 15, 2024Inventors: Tracy Goeken, Bernard Winkler
-
Publication number: 20240050471Abstract: The present disclosure provides for methods of activating an immune cell in a subject by administering to the subject a CYR61 activating agent, as well as methods of treating ocular neovascularization in a subject by administering a CYR61 activating agent to an immune cell to form a treated immune cell and administering the treated immune cell to the subject.Type: ApplicationFiled: August 11, 2023Publication date: February 15, 2024Applicant: Washington UniversityInventors: Rajendra Apte, Joseph Lin, Philip Ruzycki
-
Publication number: 20240050472Abstract: Provided are an anti-Claudin 18.2 antigen-binding fragment or antibody, and the use thereof. CDR3 of a heavy chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 3. CDR3 of a light chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 6. The provided antigen-binding fragment and anti-Claudin 18.2 antibody can specifically bind to a variety of sources of Claudin 18.2 proteins, have no binding effect on other proteins, and have a high specificity. In addition, a chimeric antigen receptor and a CAR-T cell prepared by means of the antibody have obvious cytotoxicity on cells stably expressing the Claudin 18.2 protein.Type: ApplicationFiled: December 22, 2020Publication date: February 15, 2024Applicant: GUANGZHOU BIO-GENE TECHNOLOGY CO., LTDInventors: Min Luo, Guangchao Li, Wen Ding, Zhao Zhou, Xuejun Wang
-
Publication number: 20240050473Abstract: Antigen binding agents (e.g., single domain antibodies) that bind guanylyl cyclase C (GCC) and chimeric antigen receptors comprising GCC antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions comprising these antigen binding agents and fragments thereof are also disclosed. The invention also provides therapeutic methods for utilizing the antibodies and antigen-binding molecules are provided herein.Type: ApplicationFiled: December 9, 2021Publication date: February 15, 2024Inventors: Gary SHAPIRO, Johara CHOUITAR, Xingyue HE, Mei Rosa NG
-
Publication number: 20240050474Abstract: Provided are engineered cells (such as stem cells or T cells) that have a surface molecule comprising a membrane-tethered binding moiety that binds to a T cell surface antigen (such as CCR5, CD4 or CXCR4) or a HIV antigen, or a membrane tethered inhibitory moiety that inhibits the membrane fusion of HIV (such as C34). Also provided are methods of making and using these engineered cells.Type: ApplicationFiled: February 8, 2022Publication date: February 15, 2024Inventors: Ming Zeng, Weiming Wang
-
Publication number: 20240050475Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds to human PRDX4 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides said pharmaceutical composition for use in a method for the treatment of cancer in a human subject. Further is provided a method for determining whether a human subject may suffer from cancer, comprising determining in a sample obtained from said human subject whether PRDX4 is present on the cell surface of cells comprised by said sample. Additionally, an antibody which binds to human PRDX4 present on the cell surface of a target cell is provided.Type: ApplicationFiled: December 10, 2021Publication date: February 15, 2024Inventor: Reinhard Zeidler
-
Publication number: 20240050476Abstract: The invention relates to methods for treatment of cancers utilizing a combination of a deoxyribonuclease enzyme and adoptive cell immunotherapy comprising cells expressing a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In particular embodiments, the deoxyribonuclease enzyme can be given parenterally or encoded by a vector or secreted by a cell comprising TCR or CAR.Type: ApplicationFiled: January 7, 2022Publication date: February 15, 2024Applicant: CLS THERAPEUTICS LIMITEDInventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich TETS, Viktor Veniaminovich TETS, Alexey Vyacheslavovich STEPANOV
-
Publication number: 20240050477Abstract: The present invention provides a lipid nanoparticle and the like containing a pH-sensitive cationic lipid represented by formula (1) (in formula (1), R1 and R2 are each independently a straight-chain C10-14 alkyl group, a straight-chain C10-20 alkenyl group having one or two unsaturated bonds, or —CH(R5)(R6)(where R5 and R6 are each independently a straight-chain C5-10 alkyl group); p represents an integer of 3-8; and R3 and R4 are each independently a methyl group or an ethyl group].Type: ApplicationFiled: February 17, 2022Publication date: February 15, 2024Applicant: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Takashi Nakamura, Hideyoshi Harashima, Yusuke Sato, Koharu Yamada, Taisei Nakade
-
Publication number: 20240050478Abstract: The present invention relates to a method for producing natural killer cells using T cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using CD4 (+) T cells as feeder cells. The method for producing natural killer cells using T cells according to the present invention is a method capable of producing natural killer cells by selectively proliferating only natural killer cells from a small amount of seed cells while maintaining the high killing activity of the natural killer cells. The method of the present invention can produce a large amount of natural killer cells that can be frozen, and thus is useful for commercialization of cell therapeutic agents.Type: ApplicationFiled: August 24, 2023Publication date: February 15, 2024Inventors: Bo Kyung Min, Hana Choi, Yu Kyeong Hwang
-
Publication number: 20240050479Abstract: The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.Type: ApplicationFiled: October 5, 2023Publication date: February 15, 2024Inventors: Martin E. Sanders, Vidyasagar Vuligonda
-
Publication number: 20240050480Abstract: The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.Type: ApplicationFiled: October 26, 2023Publication date: February 15, 2024Inventor: Michael Har-Noy
-
Publication number: 20240050481Abstract: The present disclosure includes a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising a blister-derived cell of a patient with dystrophic epidermolysis bullosa that is genetically modified to produce type VII collagen.Type: ApplicationFiled: July 21, 2021Publication date: February 15, 2024Applicants: OSAKA UNIVERSITY, STEMRIM INC.Inventors: Katsuto TAMAI, Yasushi KIKUCHI, Tomoki TAMAKOSHI, Takehiko YAMAZAKI
-
Publication number: 20240050482Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: January 26, 2023Publication date: February 15, 2024Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20240050483Abstract: In various aspects and embodiments, this disclosure provides methods for generating hematopoietic stem cells (HSCs), as well as compositions comprising the same, and methods of treating disease. The disclosure provides methods for preparing endothelial cells from pluripotent stem cells by expression (e.g., overexpression) of E26 transformation-specific variant 2 (ETV2) transcription factor. HSCs are then generated from the endothelial cells using mechanical, biochemical, pharmacological and/or genetic stimulation.Type: ApplicationFiled: December 10, 2021Publication date: February 15, 2024Inventor: Dhvanit SHAH
-
Publication number: 20240050484Abstract: The present invention relates to a cell gel preparation, which is used for treating and/or preventing acute or chronic osteoarthritis and/or symptoms thereof by means of intra-articular injection, wherein the preparation comprises a nucleic acid hydrogel loading mesenchymal stem cells. The present invention further relates to a method for treating or preventing acute and chronic osteoarthrosis and associated symptoms caused by inflammation (especially osteoarticular pain and activity or function loss) by means of using the cell gel preparation, and a method for reducing the shear damage on cells in a shear environment by means of using the nucleic acid hydrogel.Type: ApplicationFiled: October 8, 2021Publication date: February 15, 2024Inventors: Dongsheng Liu, Jiakuo Yu, Bo Yang, Xin Yan, Yujie Li, Bini Zhou, Xin Li
-
Publication number: 20240050485Abstract: Disclosed are means, treatments and compositions of matter useful for treatment of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse reduction in lung function associated with COPD. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of pulmonary regeneration directly or indirectly.Type: ApplicationFiled: August 14, 2023Publication date: February 15, 2024Inventors: Thomas E. ICHIM, Timothy G. DIXON, Feng LIN, James VELTMEYER
-
Publication number: 20240050486Abstract: The present disclosure provides methods for generating cortical excitatory neurons, cortical excitatory neurons generated by such methods, and composition comprising such cells. The present disclosure also provides uses of the cortical excitatory neurons and composition comprising thereof for preventing and/or treating neurodegenerative disorders.Type: ApplicationFiled: July 7, 2023Publication date: February 15, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied DiseasesInventors: Lorenz Studer, Gabriele CICERI
-
Publication number: 20240050487Abstract: The present disclosure relates to an immuno-potentiating composition, more specifically to a composition containing an enzymatic extract of deer antler with excellent NK cell activity as an active ingredient, which exhibits immuno-potentiating effect by proliferating immune cells and particularly enhancing NK cell activity and, as such, can be used as a food composition and further as a health functional food or pharmaceutical composition for immuno-potentiation.Type: ApplicationFiled: December 29, 2021Publication date: February 15, 2024Applicant: YUHAN CARE CO., LTD.Inventors: Jongsoo KANG, Kyung In CHUNG, Il PARK, Hyun Je PARK, Aeri SONG, Semi EOM, Hye Jin JEON, Sin Hwa BAEK
-
Publication number: 20240050488Abstract: A method of treating diaper rash in a subject is provided. A method of treating athlete's foot in a subject is provided. A method of treating contact dermatitis in a subject is provided. A method of treating perspiration and body odor in a subject is provided. The method comprises administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject, thereby treating the diaper rash, athlete's foot, contact dermatitis, or perspiration and body odor. Related preparations, kits, and devices are also provided.Type: ApplicationFiled: October 26, 2023Publication date: February 15, 2024Inventors: Todd Krueger, David R. Whitlock, Lauren Nicole Ambrogio, Larry Weiss
-
Publication number: 20240050489Abstract: The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.Type: ApplicationFiled: October 12, 2023Publication date: February 15, 2024Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Matthew J. HAMILTON, Alexander KHORUTS, Michael J. SADOWSKY, Christopher M. STALEY
-
Publication number: 20240050490Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.Type: ApplicationFiled: July 11, 2023Publication date: February 15, 2024Applicant: Seres Therapeutics, Inc.Inventors: Gregory MCKENZIE, Mary-Jane LOMBARDO MCKENZIE, David N. COOK, Marin VULIC, Geoffrey VON MALTZAHN, Brian GOODMAN, John Grant AUNINS, Matthew R. HENN, David Arthur BERRY, Jonathan WINKLER
-
Publication number: 20240050491Abstract: A method of generating an antimicrobial agent is disclosed. The method comprises: (a) culturing Bacillus cells in a medium under conditions effective to allow secretion of at least one antimicrobial agent into the medium; and (b) purifying the at least one antimicrobial agent from the medium to generate a purified preparation comprising the at least one antimicrobial agent. Uses of the antimicrobial agents secreted from the Bacillus cells are also disclosed.Type: ApplicationFiled: September 14, 2023Publication date: February 15, 2024Applicant: The state of Israel, Ministry of Agriculture & Rural Development, Agricultural Research OrganizationInventors: Moshe SHEMESH, Yulia KROUPITSKI, Shlomo SELA
-
Publication number: 20240050492Abstract: The present disclosure describes probiotic compositions comprising Emergencia timonensis and methods for using probiotic compositions comprising Emergencia timonensis to reducing TMA and/or TMAO levels in subjects in need thereof.Type: ApplicationFiled: August 15, 2023Publication date: February 15, 2024Applicant: Oregon State UniversityInventors: Veronika Kivenson, Stephen J. Giovannoni
-
Publication number: 20240050493Abstract: The present invention relates to a composition comprising Pediococcus pentosaceus LB606R, deposited under the assession number DSM 33730; Lactiplantibacillus plantarum, LB679R, deposited under the assession number DSM 33731; or a combination hereof.Type: ApplicationFiled: December 29, 2021Publication date: February 15, 2024Applicant: Lactobio A/SInventors: Charlotte VEDEL, Katja BILLEKOP OLSEN, Jens Edward TESDORPF, Søren KJÆRULFF
-
Publication number: 20240050494Abstract: Disclosed herein are methods and compositions useful for the treatment of subjects suffering from Prader-Willi Syndrome (PWS). The methods include administering compositions comprising probiotics, such as Lactobacillus reuteri (L. reuteri) and Bifidobacterium animalis subsp. lactis (B. lactis) to subjects in need thereof.Type: ApplicationFiled: December 17, 2021Publication date: February 15, 2024Inventor: Xue-Jun Kong
-
Publication number: 20240050495Abstract: Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.Type: ApplicationFiled: June 30, 2022Publication date: February 15, 2024Applicant: GI BIOME INC.Inventors: Bo Gie YANG, Myung Ho JANG, Han Sung LEE
-
Publication number: 20240050496Abstract: A probiotic composition comprising Bacillus amyloliquefaciens, Enterococcus faecalis, Lactobacillus salivarius, Lactobacillus johnsonii, Lactobacillus gallinarum and Lactobacillus crispatus is provided. The probiotic composition stimulates the immune response of chickens without negatively affecting growth performance. The probiotic composition can be added to poultry feed to improve the health and performance of chickens, and can be used as a replacement for antibiotic supplementation.Type: ApplicationFiled: October 19, 2023Publication date: February 15, 2024Inventors: Deon Pieter Neveling, Leon Milner Theodore Dicks
-
Publication number: 20240050497Abstract: Use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.Type: ApplicationFiled: October 24, 2023Publication date: February 15, 2024Inventors: Simone Domenico GUGLIELMETTI, Ruggero ROSSI, Walter FIORE, Andrea BIFFI
-
Publication number: 20240050498Abstract: The formation method was revealed of a bacteriophage synergistic composition intended to prevent and combat infections of livestock, including but not limited to poultry, with pathogenic bacteria strains sensitive to the phages.Type: ApplicationFiled: June 28, 2021Publication date: February 15, 2024Applicant: Proteon Pharmaceuticals S.A.Inventors: Jaroslaw DASTYCH, Ewelina A. WÓJCIK, Agnieszka MASZEWSKA, Malgorzata STANCZYK, Anna PEKALA, Edyta SMIGIELSKA, Ewelina WOJDA, Joanna KAZIMIERCZAK, Arkadiusz GUZI?SKI, Justyna ANDRYSIAK, Paulina WIGNER
-
Publication number: 20240050499Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.Type: ApplicationFiled: October 31, 2023Publication date: February 15, 2024Inventors: Seong Jun YOON, Jee Soo SON, In Hwang KIM, Hyoung Rok PAIK, Eun Kyoung OH, Soo Youn JUN, Sang Hyeon KANG
-
Publication number: 20240050500Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.Type: ApplicationFiled: October 31, 2023Publication date: February 15, 2024Inventors: Seong Jun YOON, Jee Soo SON, In Hwang KIM, Hyoung Rok PAIK, Eun Kyoung OH, Geun Woo LEE, Soo Youn JUN, Sang Hyeon KANG
-
Publication number: 20240050501Abstract: The invention discloses a method for forming a fungi fermentation product containing N-acetylglucosamine. The fungi fermentation product containing N-acetylglucosamine can convert cancer cells into normal cells through a mesenchymal epithelial transition mechanism. The method uses fungi as a starting material which together with a Cordyceps-related fungus is fermented to form a fermentation product which induces a mesenchymal epithelial transition to convert cancer cells into normal cells. The fungi cell wall contains chitin. The fermentation liquid is produced by fermentation of Cordyceps with chitin as the substrate. The main product is N-acetylglucosamine confirmed by an HPLC analysis. According to the experimental data, the fermentation product of N-acetylglucosamine converts cancer cells into epithelial cells that contain E-cadherin and has a square shape.Type: ApplicationFiled: March 22, 2023Publication date: February 15, 2024Inventor: Kun-Lin Yang
-
Publication number: 20240050502Abstract: Disclosed are compositions containing two purified Amanita muscaria compounds chosen from the following: ibotenic acid, muscimol, muscazone, stizolobic acid, stizolobinic acid, muscarine, muscamfin, muscaflavin, betalamic acid, muscapurpurin, muscaaurins, acetylcholine, atropine, hyoscyamine, L-3,4-dihydroxyphenylalanine, phallolysin, scopolamine, fucomannogalactan, B(1?6)-branched (1?3)-?-d-glucan, amatoxins, phallotoxins, or the salts of these Amanita muscaria compounds. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient. Pharmaceutical formulations further containing a therapeutically effective amount of a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene a disclosed. Also disclosed are methods of regulating the activity of a neurotransmitter receptor and methods of treating a psychological disorder, a compulsive disorder, or a depressive disorder.Type: ApplicationFiled: December 14, 2021Publication date: February 15, 2024Inventor: Andrew R. CHADEAYNE
-
Publication number: 20240050503Abstract: A method can relate to the use of flower essence-containing medicaments, particularly those that are useful for the alleviation of stress. More particularly, though not exclusively, a method can relate to topical applications including creams, such as facial and body cream, oils, spritzers and toners and serums, for oral and/or external application, that are useful for the alleviation of stress. Compositions provide a combination of advantageous properties of a cosmetic composition including one or more of Appearance, Odour, Ease of Application, Ease of Absorbency, Absorbency time, Greasiness (lower score if greasier), Irritation, Skin, Feel (softness) and Skin Moisturisation. Compositions can include one or more plant stem cell extracts in combination with one or more flower essences. A composition can preferably include extracts from Fitzroya cupressoide.Type: ApplicationFiled: August 3, 2022Publication date: February 15, 2024Inventors: Clare G. Harvey, Dori Naerbo
-
Publication number: 20240050504Abstract: The present invention relates to the preparation technical field of traditional Chinese medicine and more particularly, to a traditional Chinese medicine eye drops and the preparation method thereof. The traditional Chinese medicine components of the traditional Chinese medicine eye drops provided by the embodiments of the invention comprise: ginseng radix et rhizoma of 5-10 wt %, scrophulariae radix of 15-20 wt %, xanthii fructus of 5-10 wt %, bovis calculus sativus of 5-10 wt %, carthami flos of 5-10 wt %, borneolum of 5-10 wt %, senecionis scandentis herba of 25-35 wt %, fibraureae caulis of 5-15 wt % and motherwort fruit of 5-10 wt %.Type: ApplicationFiled: August 11, 2022Publication date: February 15, 2024Inventor: See Tung Kwan
-
Publication number: 20240050505Abstract: Disclosed is a method for treating skin. The method can include topically applying to skin in need thereof a composition comprising effective amounts of Arctium lappa root extract and Epilobium angustifolium extract to reduce expression of a pro-inflammatory cytokine of IL-8, IL-2, or TNF-? in the skin.Type: ApplicationFiled: March 20, 2023Publication date: February 15, 2024Inventors: Michelle HINES, Tiffany CARLE
-
Publication number: 20240050506Abstract: A steviol glycoside composition with reduced surface tension. The reduced surface tension steviol glycoside composition includes an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension. Method for reducing surface tension in a steviol glycoside solution includes contacting a steviol glycoside and a surface tension reducing compound.Type: ApplicationFiled: June 2, 2023Publication date: February 15, 2024Applicant: CARGILL, INCORPORATEDInventors: Dan S. GASPARD, Adam John STEINBACH, Adam T. ZARTH
-
Publication number: 20240050507Abstract: A method for preparing a Plectranthus amboinicus (PA) extract, the method comprising extracting an above-ground part of Plectranthus amboinicus with an extracting solution that comprises a solvent having a suitable polarity index, filtrating and concentration the extract thus produced, and subject the concentrated extract to a chromatographic separation process using a hydrophobic interaction chromatography resin to produce the PA extract.Type: ApplicationFiled: October 27, 2023Publication date: February 15, 2024Applicant: Oneness Biotech Co., Ltd.Inventors: Yueh-Ju Wang, Kung-Ming Lu
-
Publication number: 20240050508Abstract: A pharmaceutical product of the present invention contains plant parts obtained from the neem tree Azadirachta indica or active ingredients derived from such plant parts for use in treating, preventing and/or alleviating symptoms of restless legs syndrome.Type: ApplicationFiled: October 27, 2023Publication date: February 15, 2024Inventor: Martin VORDERWÜLBECKE
-
Publication number: 20240050509Abstract: Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.Type: ApplicationFiled: February 21, 2023Publication date: February 15, 2024Applicant: KUALITY HERBCEUTICS LLCInventors: Chengguo Xing, Stephen Hecht, Junxuan Lu, Pramod Upadhyaya, Sharon Murphy, Pablo Leitzman, Sreekanth Narayanapillai, Silvia Balbo
-
Publication number: 20240050510Abstract: The present invention concerns methods and compositions employing a combination of Uncaria rhynchophylla (UR) herb and an antidepressant or anxiolytic drug therapy for treating or preventing anxiety, stress, depression, and/or symptoms thereof, wherein the combined administration of UR and the drug elicit a fast on-set response in the subject.Type: ApplicationFiled: December 9, 2021Publication date: February 15, 2024Applicant: THE OPEN UNIVERSITYInventor: Ravid DORON
-
Publication number: 20240050511Abstract: Methods for promoting intestinal health of a subject in need thereof and for enhancing antioxidation in a subject in a subject in need thereof are provided. The methods include administering to the subject a prebiotic composition, which includes grape ferment, lactitol, and fructooligosaccharide. The weight ratio of the grape ferment, the lactitol, and the fructooligosaccharide falls within the range of 1-2:1-2:1-2. The grape ferment is obtained by fermenting grape extract with Saccharomyces cerevisiae and Streptococcus thermophilus.Type: ApplicationFiled: October 27, 2023Publication date: February 15, 2024Inventors: YUNG-HSIANG LIN, CHU-HAN HUANG
-
Publication number: 20240050512Abstract: The present invention relates to a composition comprising one or more of clove oil, eucalyptus oil, basil oil, ginger oil, an extract or component of any of these, or a combination thereof, and to a buffer composition having a pH of from 6.7 to 7.9 at a temperature of 37° C., both for use in the treatment, prophylactic treatment or amelioration of an airborne viral infection, or for use in reducing viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection in the subject. The present invention also relates to an aqueous composition either comprising a buffer and an essential oil with antiviral, antibacterial or antifungal activity; or comprising a buffer, hydrogen carbonate ions, and zinc ions; or comprising a buffer, hydrogen carbonate ions, and transferrin and/or iron ions. The present invention also relates to methods of preparing the compositions, and to concentrates of the compositions.Type: ApplicationFiled: November 25, 2021Publication date: February 15, 2024Inventors: Mohammed Abid Masood, Rakesh Uppal, Angela Russell, Laurence Silpa
-
Publication number: 20240050513Abstract: A peptide with terminal tyrosine has an excellent effect on inhibiting protein nitration and also an excellent effect on preventing, ameliorating, or treating disease symptoms in chronic immobilization stress-induced depression/cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.Type: ApplicationFiled: February 23, 2022Publication date: February 15, 2024Inventors: Hyun Joon KIM, Young Bum KIM, Jae Soon KANG, Soonwoong JUNG, Miyoung SONG, Ji Hyeong BAEK, Sang Won PARK, Hwajin KIM, Dae Young YOO